title: Nicotine Increases Codeine Analgesia Through the Induction of Brain CYP2D and Central Activation of Codeine to Morphine.
abstract: CYP2D metabolically activates codeine to morphine, which is required for codeine analgesia. Permeability across the blood-brain barrier, and active efflux, suggests that initial morphine in the brain after codeine is due to brain CYP2D metabolism. Human CYP2D is higher in the brains, but not in the livers, of smokers and 7-day nicotine treatment induces rat brain, but not hepatic, CYP2D. The role of nicotine-induced rat brain CYP2D in the central metabolic activation of peripherally administered codeine and resulting analgesia was investigated. Rats received 7-day nicotine (1 mg/kg subcutaneously) and/or a single propranolol (CYP2D mechanism-based inhibitor; 20 μg intracerebroventricularly) pretreatment, and then were tested for analgesia and drug levels following codeine (20 mg/kg intraperitoneally) or morphine (3.5 mg/kg intraperitoneally), matched for peak analgesia. Nicotine increased codeine analgesia (1.59X AUC(0-30 min) vs vehicle; p<0.001), while propranolol decreased analgesia (0.56X; p<0.05); co-pretreatment was similar to vehicle controls (1.23X; p>0.1). Nicotine increased, while propranolol decreased, brain, but not plasma, morphine levels, and analgesia correlated with brain (p<0.02), but not plasma (p>0.4), morphine levels after codeine. Pretreatments did not alter baseline or morphine analgesia. Here we show that brain CYP2D alters drug response despite the presence of substantial first-pass metabolism of codeine and further that nicotine induction of brain CYP2D increases codeine response in vivo. Thus variation in brain CYP2D activity, due to genetics or environment, may contribute to individual differences in response to centrally acting substrates. Exposure to nicotine may increase central drug metabolism, not detected peripherally, contributing to altered drug efficacy, onset time, and/or abuse liability.
authors: Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH) and Departments of Psychiatry, Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
authors: Douglas M
authors: DM
authors: McMillan
authors: Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health (CAMH) and Departments of Psychiatry, Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
authors: Rachel F
authors: RF
authors: Tyndale
mesh_terms: D000818:Animals; D019540:Area Under Curve; D001921:Brain / Q000187:drug effects*; D002851:Chromatography, High Pressure Liquid; D003061:Codeine / Q000494:pharmacology*; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000494:pharmacology; D008297:Male; D009020:Morphine / Q000494:pharmacology*; D009294:Narcotics / Q000494:pharmacology*; D009538:Nicotine / Q000494:pharmacology*; D018722:Nicotinic Agonists / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
chemical_list: D004791:Enzyme Inhibitors; D009294:Narcotics; D018722:Nicotinic Agonists; D009538:Nicotine; D009020:Morphine; D003577:Cytochrome P-450 Enzyme System; D003061:Codeine
references: Psychopharmacology (Berl). 2001 Aug;157(1):40-5
references: 11512041
references: J Psychiatry Neurosci. 2008 Jan;33(1):54-63
references: 18197273
references: Pharm Res. 2000 Oct;17(10):1220-7
references: 11145227
references: Br J Pharmacol. 2014 Jun;171(12):3077-88
references: 24611668
references: Neuropsychopharmacology. 2011 Feb;36(3):692-700
references: 21107310
references: Eur J Pharmacol. 2008 Jun 10;587(1-3):169-74
references: 18466896
references: Eur J Clin Pharmacol. 1992;42(6):587-91
references: 1623898
references: Neuropharmacology. 2008 Dec;55(7):1147-55
references: 18687346
references: Biochem Pharmacol. 1995 Feb 14;49(4):453-60
references: 7872951
references: Biol Pharm Bull. 2001 Sep;24(9):988-94
references: 11558582
references: Drug Metab Rev. 2004 May;36(2):313-33
references: 15237857
references: Pharmacol Rev. 2001 Dec;53(4):597-652
references: 11734620
references: Clin Pharmacol Ther. 1990 Dec;48(6):686-93
references: 2249379
references: Prim Care. 1999 Sep;26(3):611-31
references: 10436290
references: J Pharmacol Exp Ther. 1955 Jul;114(3):251-62
references: 13243236
references: Annu Rev Pharmacol Toxicol. 2003;43:149-73
references: 12171978
references: J Neurosci. 2002 Dec 15;22(24):10935-40
references: 12486188
references: Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):23-37
references: 14618296
references: Proc Natl Acad Sci U S A. 1994 Feb 1;91(3):1019-23
references: 8302826
references: Br J Clin Pharmacol. 1994 Jul;38(1):9-14
references: 7946944
references: Biochem Pharmacol. 1997 Jun 1;53(11):1605-12
references: 9264312
references: Clin Pharmacokinet. 1994 Feb;26(2):144-60
references: 8162658
references: Br J Clin Pharmacol. 1991 Apr;31(4):381-90
references: 2049245
references: J Clin Psychopharmacol. 2000 Aug;20(4):435-44
references: 10917405
references: Pharmacogenetics. 1997 Oct;7(5):375-9
references: 9352573
references: Ann Epidemiol. 2010 Dec;20(12):890-7
references: 20627770
references: Drug Metab Dispos. 2002 Sep;30(9):970-6
references: 12167561
references: Am J Addict. 2013 Nov-Dec;22(6):581-9
references: 24131166
references: N Engl J Med. 1993 Aug 19;329(8):552-60
references: 8336756
references: Psychopharmacology (Berl). 2006 Mar;184(3-4):401-8
references: 16485141
references: J Addict Dis. 2000;19(4):35-52
references: 11110063
references: Clin Pharm. 1990 Feb;9(2):125-35
references: 2407422
references: Clin Pharmacol Ther. 2008 Feb;83(2):234-42
references: 17971818
references: Proc Natl Acad Sci U S A. 1973 Aug;70(8):2243-7
references: 4525427
references: Biochem Pharmacol. 2013 Jun 15;85(12):1848-55
references: 23623752
references: CMAJ. 2006 Nov 21;175(11):1385
references: 17116905
references: Neuroscience. 2001;106(1):129-36
references: 11564423
references: J Adolesc Health. 2014 Nov;55(5):595-7
references: 25344030
references: Science. 1972 Dec 1;178(4064):984-6
references: 5084666
references: Toxicol Sci. 2012 Apr;126(2):325-35
references: 22287024
references: Neurobiol Aging. 2012 Sep;33(9):2160-71
references: 21958961
references: Neuropharmacology. 2000 Oct;39(13):2785-91
references: 11044748
references: J Pharmacol Exp Ther. 1953 Mar;107(3):385-93
references: 13035677
references: J Neurochem. 1995 Apr;64(4):1878-83
references: 7891117
references: Life Sci. 1990;46(15):1067-74
references: 2333013